)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Amphastar Pharmaceuticals (AMPH) investor relations material
Amphastar Pharmaceuticals Jefferies London Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Jefferies London Healthcare Conference 2025 summary19 Nov, 2025
Business Overview and Strategic Vision
Focus has shifted from complex generics to proprietary and biosimilar products, supported by a fully integrated model covering R&D, manufacturing, and distribution.
Dual growth strategies include organic pipeline development and inorganic growth through strategic acquisitions.
Baqsimi and Primatene Mist achieved double-digit growth, with Baqsimi's international reach expanded to 26 countries and projected peak sales of $250–$275 million.
Collaboration with Mankind doubled sales force reach for Baqsimi.
Operates with a focus on high quality, efficiency, and technology, resulting in rising net income margins and strong revenue growth from 2018 to 2024.
Pipeline Strategy, Evolution, and Regulatory Environment
Pipeline is shifting from 63% generics in 2021 to a projected 50% proprietary and 35% biosimilar by 2026, including three in-licensed peptide NCEs.
FDA's new biosimilar guidance shortens development timelines, supporting biosimilar strategy.
Four biosimilar products in the pipeline, with a focus on insulins and an undisclosed product with manufacturing advantages.
Two major launches planned for 2026: AMP-015 (generic teriparatide) and AMP-007 (generic HFA inhaler), with AMP-007 expected to be the first generic entrant and eligible for 180 days exclusivity.
In-licensed three novel peptide assets (AMP-105, AMP-107, AMP-109) targeting oncology and ophthalmology, with a potential market exceeding $60 billion.
Product Portfolio, Growth Drivers, and Market Positioning
Key products include Primatene Mist (only OTC asthma inhaler), Baqsimi (intranasal glucagon, 56%-60% market share), and a broad diabetes portfolio covering GLP-1 and multiple insulin biosimilars.
Primatene Mist forecasts high single-digit growth in 2025, supported by a new green propellant and increased physician sampling; patent expires January 2026, with a next-gen product already patented.
Baqsimi growth driven by increased awareness, collaboration, and only 12% of insulin patients currently prescribed glucagon.
Ongoing evaluation of marketing investment for Baqsimi, with flexibility to increase as opportunities arise.
BAQSIMIⓇ acquisition expands international reach and is a key growth driver for 2025/2026.
Confidence in AMP-007 mid-2026 launch despite GDUFA delay?
How will R&D for proprietary pipeline impact 2026 margins?
Rationale for no Primatene Mist generic post-2026 IP expiry?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Amphastar Pharmaceuticals earnings date
Piper Sandler 37th Annual Healthcare Conference3 Dec, 2025
Next Amphastar Pharmaceuticals earnings date
Piper Sandler 37th Annual Healthcare Conference3 Dec, 2025
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Amphastar Pharmaceuticals Inc. is a specialty pharmaceutical company engaged in the development, manufacture, and marketing of generic and proprietary injectable, inhalation, and intranasal products. The company focuses on producing pharmaceuticals for hospital, emergency, and clinical use, including treatments for respiratory conditions, diabetes, and pain management. Amphastar operates manufacturing and research facilities to support its product portfolio and pipeline development. Amphastar Pharmaceuticals Inc. is headquartered in Rancho Cucamonga, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage